GlassScriptPhysician profile
Sara Roberson
NPI 1285862540
$1,849.00
in general payments reported to CMS, 2019-2025
18 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.65 · 2020: $11.22 · 2022: $209 · 2023: $218 · 2024: $628 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $835.59 | 2022-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $256.51 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $255.39 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $71.61 | 2019-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $70.89 | 2024-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $69.90 | 2022-2024 | Epclusa |
| Glaxosmithkline, LLC. | $49.19 | 2022-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $32.86 | 2025 | |
| Pfizer INC. | $32.85 | 2019-2024 | |
| Lilly USA, LLC | $29.59 | 2022-2024 | Zepbound, Mounjaro |
| Lundbeck LLC | $22.83 | 2025 | Rexulti |
| Alkermes, INC. | $21.60 | 2025 | Aristada, Lybalvi |
| Novo Nordisk INC | $21.55 | 2024 | Rybelsus |
| Electromed, INC. | $18.49 | 2025 | Smartvest |
| The Binding Site INC. | $17.70 | 2025 | Freelite |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cashflow Solutions, LLC | $15.73 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.50 | 2023 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.